UCCER
Role: President
Author, Gerontologist, Health Care Provider, Environmentalist, Human Rights Defender, Development Strategist and founder of the Centre of Excellence on Ageing an Initiative of the Zambian International Health Alliance CEO.Was the first Zambian to set up an organization to advocate against Elder Abuse called [Afro-Elder International] that pushed the Chiluba The government in the late 90’s to come up with the International Day of Older Persons, which is celebrated in Zambia every 1st October.
Advisor and Consultant with the Zambia National Marketeers Credit Association [ZANAMACA] an NGO with over 3 million members who are entrepreneurs in the Informal Sector with start up businesses that have over the years grown.
Search jobs FDA Approves Amgen s RIABNI(TM) (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)
THOUSAND OAKS, Calif., Dec. 17, 2020 /PRNewswire/ Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan
® (rituximab), for the treatment of adult patients with Non-Hodgkin s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener s Granulomatosis), and Microscopic Polyangiitis (MPA). RIABNI will be made available in the U.S. in January 2021. The approval of RIABNI represents an important milestone across our biosimilar and oncology portfolios, said Murdo Gordon, executive vice president of Global Commercial Operations at Amgen. Following the proven success of KANJINTI
Amgen today announced that the U.S. Food and Drug Administration has approved RIABNI™ a biosimilar to Rituxan ® for the treatment of adult patients with Non-Hodgkin’s Lymphoma Chronic Lymphocytic Leukemia Granulomatosis with Polyangiitis and Microscopic Polyangiitis . RIABNI will be made available in the U.S. in January 2021 . “The approval of RIABNI represents an important milestone across our biosimilar and …
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan ® (rituximab), for the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis), and Microscopic Polyangiitis (MPA). RIABNI will be made available in the U.S. in January 2021 .
Szczepionka Moderny dopuszczona do użytku w USA Kiedy trafi do Polski? sputniknews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sputniknews.com Daily Mail and Mail on Sunday newspapers.
Northwest Arkansas hospitals hopeful about COVID-19 vaccine, give update on hospital space
Hospital leaders in Northwest Arkansas are hopeful about the vaccine but say the number of COVID-19 cases and hospitalizations continues to be on the rise. Author: 5NEWS Web Staff Updated: 5:30 AM EST December 16, 2020
ROGERS, Arkansas On Monday (Dec. 14), a Northwest Arkansas council provided the following information on behalf of the Northwest Arkansas health care community, to help inform and educate the region.
Northwest Arkansas hospitals are hopeful about the vaccine but say the number of COVID-19 cases and hospitalizations continues to be on the rise. As of Dec. 14, 107 patients are in NWA hospital COVID units.